article thumbnail

Longford Argues Patent Settlement Row Must Be Arbitrated

IP Law 360

Litigation funder Longford Capital has asked a Delaware federal court to send its dispute over a settlement with Arigna Technology Ltd. to arbitration, saying the arbitration agreement between the two parties is valid despite the Irish patent holding company's claims otherwise.

article thumbnail

Competition Bureau closes two investigations into pharmaceutical patent litigation settlements

JD Supra Law

On May 20, 2022, the Competition Bureau announced that it closed two investigations into pharmaceutical patent litigation settlement agreements as evidence gathered during the two investigations suggested the agreements did not contravene the Competition Act. The parties and drugs involved were not identified.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ANDA Litigation Settlements - Summer 2021

JD Supra Law

This chart summarizes the case name, drug, patents-in-suit, and publicly available terms for reported settlements in federal district court cases that are filed pursuant to the Hatch-Waxman Act. By: Robins Kaplan LLP

article thumbnail

Clarity May Be Around the Corner for Antitrust Scrutiny of Reverse Payment Settlements

JD Supra Law

Actavis that reverse payment settlements—or settlements where a patent holder pays an accused patent infringer cash or other consideration to end the patent litigation—may be subject to antitrust scrutiny if they are "large and unjustified," lower courts have been in search of an administrable pleading standard for these claims.

article thumbnail

Genentech and Tanvex Reach Settlement in Principle in Trastuzumab BPCIA Litigation

JD Supra Law

On January 6, 2023, Genentech and Tanvex reached a settlement in principle to resolve all claims with respect to Genentech’s BCPIA complaint.

article thumbnail

Litigation as a Source of Profit? Non-Practicing Entities and Patent Litigation

IPilogue

Litigation is almost always recommended to be avoided , whether because of the sheer amount of time needed to get a court date, the expensive costs for the client and law firm, or the risks associated with receiving an unfavorable judgement. They do not practice, develop, manufacture, or otherwise commercialize the patent.

article thumbnail

Delaware Judge Seeks to Expose Patent-Litigation Funders

The IP Law Blog

Do defendants and the court have the right to ask who is funding a particular patent litigation? The party must identify the third-party funder and whether the third-party funder has the right to approve litigation or settlement decisions. The issue arose as a result of two standing orders issued by Judge Connolly.